Dashboard
Manage Tickers

AUPH Aurinia Pharmaceuticals Inc.

Nasdaq auriniapharma.com


$ 11.55 $ 0.00 (0 %)    

Friday, 17-Oct-2025 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 11.55
$ 11.43
$ 10.70 x 100
$ 11.67 x 20
$ 11.30 - $ 11.66
$ 6.55 - $ 13.54
971,598
na
1.52B
$ 0.97
$ 25.07
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 02-15-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-03-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-24-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

aurinia-pharmaceuticals-to-present-new-lupkynis-data-on-lupus-nephritis-at-acr-and-asn-conferences
Aurinia Pharmaceuticals to Present New LUP...
10/15/2025 10:02:53

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that five posters will be presented in collaboration with independen...

reported-earlier-aurinia-responds-to-retracted-linkedin-post-stands-behind-full-fda-approval-of-lupkynis-in-lupus-nephritis
Reported Earlier, Aurinia Responds To Retr...
09/30/2025 06:33:12

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
09/29/2025 21:06:06

Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's...

rbc-capital-maintains-outperform-on-aurinia-pharmaceuticals-raises-price-target-to-9
RBC Capital Maintains Outperform on Aurini...
08/01/2025 15:12:00

RBC Capital analyst Douglas Miehm maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Outperform and raises the price tar...

aurinia-pharmaceuticals-raises-fy2025-sales-guidance-from-25000m-26000m-to-26000m-27000m-vs-25852m-est
Aurinia Pharmaceuticals Raises FY2025 Sale...
07/31/2025 10:01:44

Aurinia Pharmaceuticals (NASDAQ:AUPH) raises FY2025 sales outlook from $250.00 million-$260.00 million to $260.00 million-$270....

aurinia-pharmaceuticals-q2-eps-016-beats-014-estimate-sales-7001m-beat-6425m-estimate
Aurinia Pharmaceuticals Q2 EPS $0.16 Beats...
07/31/2025 10:00:40

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate ...

Core News & Articles
Earnings Scheduled For July 31, 2025
07/31/2025 08:32:50

hc-wainwright--co-assumes-aurinia-pharmaceuticals-at-buy-announces-price-target-of-17
HC Wainwright & Co. Assumes Aurinia Pharma...
07/30/2025 11:12:41

HC Wainwright & Co. analyst Arthur He assumes Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy rating and announces Pric...

aurinia-pharmaceuticals-announces-results-from-a-phase-1-single-ascending-dose-study-of-aritinercept-aur200-doses-of-5-mg-25-mg-75-mg-150-mg-225-mg-and-300-mg-and-placebo-administered-by-subcutaneous-injection-in-61-healthy-subjects
Aurinia Pharmaceuticals Announces Results ...
06/30/2025 10:12:31

Aritinercept was well tolerated at all dose levels tested. There were no treatment-related Grade ≥3 adverse events, there were ...

us-stocks-likely-to-open-on-a-mixed-note-nothing-good-happens-above-a-5-yield-says-expert
US Stocks Likely To Open On A Mixed Note: ...
05/23/2025 10:15:19

U.S. stock futures were fluctuating on Friday after a mixed close on Thursday. Futures of benchmark indices were mixed in prema...

aurinias-aurora-1-analysis-links-ultra-low-proteinuria-with-favorable-lipidomic-profiles-in-lupus-nephritis
Aurinia's AURORA 1 Analysis Links Ultra-Lo...
05/22/2025 10:08:06

aurinia-pharma-swings-into-profit-as-q1-sales-jumps-24-sticks-to-guidance
Aurinia Pharma Swings Into Profit As Q1 Sa...
05/12/2025 16:56:52

Aurinia posts Q1 profit and 25% LUPKYNIS sales growth, reports $62.47 million revenue, and reaffirms full-year guidance.

aurinia-pharmaceuticals-affirms-fy2025-sales-guidance-of-25000m-26000m-vs-25787m-est
Aurinia Pharmaceuticals Affirms FY2025 Sal...
05/12/2025 10:03:04

Aurinia Pharmaceuticals (NASDAQ:AUPH) affirms FY2025 sales outlook from $250.00 million-$260.00 million to $250.00 million-$260...

aurinia-pharmaceuticals-q1-eps-016-beats-010-estimate-sales-6247m-beat-6154m-estimate
Aurinia Pharmaceuticals Q1 EPS $0.16 Beats...
05/12/2025 10:01:20

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate ...

Core News & Articles
Earnings Scheduled For May 12, 2025
05/12/2025 08:32:31

uncovering-potential-aurinia-pharmaceuticalss-earnings-preview
Uncovering Potential: Aurinia Pharmaceutic...
05/09/2025 15:02:37

autoimmune-disease-focused-aurinia-pharmaceuticals-reports-quarterly-profit-revenue-outlook-below-expectations
Autoimmune Disease-Focused Aurinia Pharmac...
02/27/2025 19:11:21

Aurinia Pharmaceuticals reported Q4 earnings of 1 cent per share, beating estimates, with LUPKYNIS sales up 36%.

aurinia-fy25-revenue-outlook-of-250m-260m-vs-2744m-estimate
Aurinia FY25 Revenue Outlook Of $250M-$260...
02/27/2025 11:03:37

Full Year 2025 Total Revenue and Net Product Sales GuidanceFor 2025, Aurinia expects total revenue in the range of $250 million...

aurinia-pharmaceuticals-q4-2024-gaap-eps-001-beats-002-estimate-sales-5987m-miss-5994m-estimate
Aurinia Pharmaceuticals Q4 2024 GAAP EPS $...
02/27/2025 11:02:00

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate ...

earnings-scheduled-for-february-27-2025
Earnings Scheduled For February 27, 2025
02/27/2025 08:32:34

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION